Denmark's recent Respiratory Syncytial Virus (RSV) vaccination program for pregnant women has shown remarkable results, according to a study from the University of Copenhagen and Nordsjællands Hospital. The study, published in The Lancet Regional Health - Europe, reveals a 75% reduction in hospital admissions among infants aged 0 to 5 months during the 2025/26 RSV season compared to the previous three seasons. This translates to over 800 infants avoiding hospital admission during the winter months, a significant achievement in the fight against RSV.
Thea Kølsen Fischer, a Clinical Professor at the Department of Public Health and co-author of the study, emphasizes the encouraging vaccination uptake, with 72% of eligible pregnant women accepting the offer in the first season. This high acceptance rate is crucial in the early stages of a vaccination program, as it helps to establish a strong foundation for future seasons.
While the study cannot establish a direct causal link between vaccination and the decline in admissions, it aligns with findings from other countries that have introduced RSV vaccination programs. The researchers highlight that changes in transmission patterns and testing activity may also have influenced the trend. However, the consistent results across multiple countries provide strong evidence for the effectiveness of RSV vaccination.
RSV, a highly infectious virus, causes inflammation and mucus build-up in the smallest airways of the lungs, making it a leading cause of respiratory infections during winter. Infants and premature babies are particularly vulnerable due to their small airways and developing immune systems. The vaccine's ability to reduce hospital admissions among young children is a significant breakthrough, as RSV can cause severe breathing difficulties and place a strain on healthcare services.
Thea Kølsen Fischer's long-term study of RSV, including her work before the first vaccines were approved in 2023, has contributed to these positive outcomes. She believes that the results reflect the impact of extensive research efforts. Caroline Klint Johannesen, a PhD student and first author of the study, shares the excitement, stating that seeing the research's practical impact is incredibly rewarding.
Despite the sharp decline in admissions, RSV is not expected to disappear completely due to its widespread nature. However, researchers are optimistic about reducing the burden of severe disease to lower levels than in previous years. The vaccine's safety and effectiveness, combined with the high acceptance rate, suggest that the program will continue to be successful in future seasons.
Thea Kølsen Fischer also highlights the potential long-term impact of the vaccine on older adults at increased risk, including those over 60 with conditions like chronic obstructive pulmonary disease (COPD). By reducing the number of older people becoming seriously ill, the vaccine could significantly control RSV's impact on the population, leading to fewer sick days and hospital admissions.
In conclusion, Denmark's RSV vaccination program has demonstrated its effectiveness in reducing hospital admissions among infants, providing a promising solution to a common winter respiratory issue. The high acceptance rate and positive results from multiple countries indicate a successful approach to combating RSV, with the potential for long-term benefits for public health.
